糖皮质激素与接受免疫检查点抑制剂治疗的类风湿关节炎合并肺癌患者生存的关联
该队列研究纳入663例接受免疫检查点抑制剂(ICI)治疗的类风湿关节炎(RA)合并转移性非小细胞肺癌(mNSCLC)的Medicare患者,46%接受糖皮质激素。时间依存Cox模型显示糖皮质激素使用与生存无关;91天界标模型中糖皮质激素剂量与生存无关(HR 1.01,95%CI 0.93,1.10)。结论认为,在用于治疗此类患者的剂量下,糖皮质激素对ICI启动后91天内的生存影响可忽略。
要点
- 在RA合并mNSCLC的ICI治疗患者中,46%接受糖皮质激素,中位平均泼尼松当量为6.59 mg/d。
- 时间依存Cox模型显示糖皮质激素使用与生存无关。
- 91天界标模型中糖皮质激素剂量与生存无关(HR 1.01;95%CI 0.93,1.10)。
核心结论
- 在用于治疗接受ICI的RA合并mNSCLC患者的剂量下,糖皮质激素对ICI启动后91天内的生存影响可忽略。
研究设计与样本
- 基于Medicare识别年龄≥66岁、mNSCLC诊断前已诊断RA、且已启动nivolumab、pembrolizumab或atezolizumab(2015-2019年,当时仅批准用于mNSCLC)的RA患者队列。
- 采用界标Kaplan-Meier曲线和时间依存校正Cox模型分析ICI启动后91天内早期糖皮质激素使用与生存的关联。
- 主要分析排除地塞米松使用者,并将其纳入敏感性分析。
- 共识别663例接受ICI治疗的RA合并mNSCLC患者,平均年龄75岁,86.9%为白人,64.7%为女性,363例(46%)接受糖皮质激素。
主要发现
- 糖皮质激素使用者中,中位平均泼尼松当量为6.59 mg/d(四分位距3.30,12.31)。
- 时间依存Cox模型中,糖皮质激素使用与生存无关。
- 91天界标模型中,糖皮质激素剂量与生存无关(HR 1.01;95%CI 0.93,1.10)。
关键数值与推荐
- 糖皮质激素使用者中位平均泼尼松当量6.59 mg/d(四分位距3.30,12.31)。
- 91天界标模型中糖皮质激素剂量与生存的HR 1.01(95%CI 0.93,1.10)。
临床怎么用
- 原文未报告临床实践建议。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Glucocorticoids are commonly used for rheumatoid arthritis (RA) treatment and to palliate some malignancies, but it is unclear whether glucocorticoids attenuate the benefits of immune checkpoint inhibitor (ICI) cancer therapy. We examined the association between glucocorticoid use and survival among ICI-treated patients with RA and metastatic nonsmall cell lung cancer (mNSCLC). METHODS: A cohort of patients with RA enrolled in Medicare were identified based on the following: age ≥66 years, RA diagnosed before mNSCLC, and having initiated nivolumab, pembrolizumab, or atezolizumab (2015-2019, when approved only for mNSCLC). Landmark Kaplan-Meier curves and time-varying adjusted Cox models were used to examine the association between early glucocorticoid use (within 91 days after ICI initiation) and survival. Dexamethasone users were excluded from the primary analysis and included in a sensitivity analysis. RESULTS: We identified 663 ICI-treated patients with RA and mNSCLC, with a mean age of 75 years, 86.9% being White, 64.7% being female, and 363 (46%) receiving glucocorticoids. Among users, the median average prednisone equivalents was 6.59 mg/d (interquartile range 3.30, 12.31). In a time-varying Cox model, glucocorticoid use was not associated with survival. Additionally, in a 91-day landmark model, glucocorticoid dose was not associated with survival (hazard ratio 1.01; 95% confidence interval 0.93, 1.10). CONCLUSION: Glucocorticoids, at the dosages used to treat ICI-treated patients with RA and mNSCLC, had a negligible effect on survival in the 91 days after ICI initiation.
引用
- Jannat-Khah D, Curtis JR, Xie F, et al. Are Glucocorticoids Associated With Worse Survival Among Patients With Rheumatoid Arthritis and Lung Cancer Treated With Immune Checkpoint Inhibitors? Arthritis Rheumatol. 2026. PMID: 41287975. doi:10.1002/art.43445
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。